MedPath

Comparison of the effect of Venlafaxine and Oxybutynin in the Treatment of Hot Flashes

Phase 2
Conditions
Breast Cancer.
Malignant neoplasm of breast
Registration Number
IRCT20210822052256N1
Lead Sponsor
Esfahan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Female
Target Recruitment
64
Inclusion Criteria

18 years or older
Pre-menopause
At least 6 months have passed since the last Menstrual Period.
Hot Flashes attacks
Willingness to participate in the study

Exclusion Criteria

Uncontrolled Hypertension
Chronic Heart Failure
Chronic Kidney Disease
Chronic Lung Failure
Chronic Liver Failure
Pregnancy
Breast feeding
Taking Anti Depressant Drugs
Taking other Medications to control Hot Flashes over the past Two weeks

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Severity of Hot Flashes. Timepoint: At the beginning of the study and 8 weeks after taking Venlafaxine or Oxybutynin. Method of measurement: Check List.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath